Single-cell Study of the Systemic Immune Response to Controlled Gluten Intake in Pediatric Celiac Disease

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study investigates how the immune system of children with celiac disease responds to controlled, small amounts of gluten. Children on a strict gluten-free diet are randomly assigned to receive either placebo, 50 mg of gluten, or 5 g of gluten once daily for three days, simulating real-life accidental exposure or dietary transgression. Blood samples are collected on Day 1 (before gluten intake) and Day 8 (five days after the last dose). Stool and urine samples are also collected for complementary analyses. Using single-cell ribonucleic acid (RNA) sequencing, T-cell receptor sequencing, microRNA profiling, and exploratory metabolomics, the study aims to characterize changes in immune cell populations and gene expression after gluten exposure. The objective is to determine whether even very small amounts of gluten induce measurable systemic immune responses and whether these responses differ according to the dose administered. Understanding these mechanisms may support the development of new biomarkers and improve clinical management of pediatric celiac disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 8
Maximum Age: 14
Healthy Volunteers: f
View:

• Age 8 to 14 years at study entry.

• Diagnosis of celiac disease according to ESPGHAN 2020 criteria.

• At least 18 months on a strict gluten-free diet (GFD).

• Adequate adherence to the GFD, demonstrated by negative fecal gluten immunogenic peptides (GIP) prior to inclusion.

• Asymptomatic from a gastrointestinal perspective in the preceding weeks.

• Ability to swallow the gluten/placebo preparation.

• Written informed consent from parents/legal guardians and assent from the child.

Locations
Other Locations
Spain
Hospital Regional Universitario de Málaga
RECRUITING
Málaga
Contact Information
Primary
Rafael Martín Masot, MD, PhD
rafammgr@uma.es
+34 951290000
Backup
Lara María Bossini Castillo, MD, PhD
lbossinicastillo@ugr.es
+34 663148283
Time Frame
Start Date: 2025-07-07
Estimated Completion Date: 2026-11
Participants
Target number of participants: 45
Treatments
Placebo_comparator: Placebo Group
Participants receive a placebo preparation once daily on Days 1, 2, and 3. Blood samples are collected on Day 1 (baseline) and Day 8 (post-intervention). Participants and evaluators remain blinded to allocation.
Experimental: Low-Dose Gluten (50 mg)
Participants receive 50 mg of gluten once daily on Days 1, 2, and 3, simulating accidental low-level exposure. Blood samples are collected on Day 1 (baseline) and Day 8 (post-intervention). Participants and evaluators remain blinded to allocation.
Experimental: High-Dose Gluten (5 g)
Participants receive 5 g of gluten once daily on Days 1, 2, and 3, simulating a dietary transgression. Blood samples are collected on Day 1 (baseline) and Day 8 (post-intervention). Participants and evaluators remain blinded to allocation.
Related Therapeutic Areas
Sponsors
Collaborators: Hospital Regional de Malaga, Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental, Centro de Investigación Biomédica, Universidad de Málaga, Biohealth Research Institute in Granada (ibs.GRANADA), Andaluz Health Service
Leads: Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud

This content was sourced from clinicaltrials.gov